Nanograb GTM brain

category

market profile

• text: Delivery to tissues beyond the liver drives partnerships between nucleic-acid drug developers and delivery-platform companies.
• text: Nanograb combines computational multivalent binder design with nanoparticle delivery; its platform is a development-stage offering, not evidence of a clinically approved treatment.

personas

• title: VP of genetic medicines R&D
  pains:

  • Promising genetic payloads may not reach the desired tissue or cell type
  • Needs to assess delivery performance before committing to a program
• title: Head of drug delivery or formulation
  pains:

  • Must improve targeting and biodistribution beyond the liver
  • Needs experimental evidence for a particular payload and disease model
• title: Biopharma partnerships lead
  pains:

  • Must evaluate platform differentiation, intellectual property and development fit
  • Needs a credible partner with a clear route from research to a deal

icp

• text: Biotech and pharmaceutical organizations developing RNA or other genetic medicines with unresolved cell-specific delivery needs; a partner profile inferred from the platform.
• text: R&D groups evaluating non-viral delivery and seeking targeting beyond liver tissue, particularly where delivery capability constrains a pipeline asset.

message pillars

• text: Aim for cell-directed genetic delivery.
• text: Use AI to support targeted delivery design.
• text: Present the work as an emerging delivery platform.

objections

• objection: Will this deliver our payload to our target cells?
  response: Request matched preclinical biodistribution, expression and selectivity data for the intended tissue and payload; avoid extrapolating from platform claims.
• objection: Is the approach scalable and safe enough to develop?
  response: Review formulation stability, manufacturing, safety and IP with the team before making a program decision.

competitors

• name: Sixfold Bioscience
  why: Develops nanoparticle systems for RNA therapeutics.
• name: Acuitas Therapeutics
  why: Develops lipid nanoparticle systems for nucleic acid delivery.
• name: GenEdit
  why: Develops polymeric nanoparticle delivery for gene-editing therapies.

influencers

• name: Debesh Mandal
  why: CEO and co-founder who discusses Nanograb's scientific and commercial development.

keywords

• targeted lipid nanoparticles
• cell specific mRNA delivery
• non viral gene delivery
• peptide targeted LNP
• extrahepatic RNA delivery
• AI drug delivery platform

voice

• Scientific and technical
• Ambitious
• Concise

signals

• text: A genetic medicine developer announces a program requiring delivery to a difficult extrahepatic tissue.
• text: A team is seeking a non-viral vector or external delivery collaboration for a specific payload.

pricing

motion

channels

• scientific conferences
• LinkedIn
• industry partnerships

confidence

Founders

• name: Debesh Mandal
  title: Founder
  role: Founder
  bio: Co-founder and CEO of Nanograb. PhD in Computational Biophysics from Imperial College London. Experienced in molecular simulations and building software for scientists. First software hire at Fabricnano
• name: Christopher Lau
  title: Founder
  role: Founder
  bio: Co-founder of Nanograb. M.Eng Biomaterials and Tissue Engineering at Imperial College London. Biomedical engineering experience developing biosensors using aptamers, and a drug delivery device for hypertension management.
• name: Shanil Panara
  title: Founder
  role: Founder
  bio: Cofounder and in silico lead at Nanograb; Imperial College PhD (dropout); Fascinated by all things compute and physics... all in the name of figuring out real life things! Otherwise, I love singing and music in general. Fun fact: I was in an a cappella group for 5 years :)